<DOC>
	<DOC>NCT00298766</DOC>
	<brief_summary>This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.</brief_summary>
	<brief_title>Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1. Male or Female 18 y/o and older 2. Female patients must be practicing an effective method of birth control 3. Biopsyproven ALamyloidosis 4. Must have been previously treated (failed at least 1 previous treatment) and in the opinion of the physician, patient requires further treatment 1. Hypersensitivity to boron or mannitol 2. Prior treatment with VELCADE 3. Patient requires other concomitant chemotherapy, radiotherapy or ancillary therapy considered investigational 4. Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>